ERK-Related Synaptic Deficits in a Mouse Model of Autism: Potential Therapeutic Solutions to an Epidemic
CSEF · 2012 Mammalian Biology Fourth Award
Overview
Objectives/Goals To interrogate whether ERK-related protein defects specific to synapses of the hippocampus are consistent across multiple mouse models of autism. Methods/Materials Hippocampal homogenates were made from subfield dissections of the bilateral hippocampi, while synaptoneurosomes were made from forebrains. Bands of Western blot analyses were visualized using ECL+ chemiluminescence (Amersham), quantified using ImageJ (NIH), and normalized to sample content. To make whole brain sections, brains were fast frozen and cryostat sectioned on the coronal plane at 20 micrometers. To conduct dual-labeled immunohistochemistry, primary and secondary antibodies were used and tissue was cover-slipped with VectaShield containing DAPI (#H-1200, Vector Labs). For hippocampal slice experiments and fast frozen brain sections, 3 to 4 tissue sections through each slice were used to acquire image z-stacks (0.2 micrometer steps). Images were processed for iterative deconvolution and automated in-house software was used to construct three-dimensional (3D) montages. The experiment used Western blot analyses and dual-labeled immunohistochemistry to independently interrogate the protein levels of ERK, p-ERK, and p-CREB in both the total CA1 hippocampus and in only the CA1 hippocampus synapses of both C57/BL6 wild-type (WT) and BTBR T+tf/J mice. Results While synaptic levels of total ERK were shown to be normal in the BTBR hippocampus, synaptic p-ERK and p-CREB levels were both demonstrated to be significantly below wild-type levels. Conclusions/Discussion ERK-related protein defects specific to hippocampal synapses were shown to be consistent across multiple unrelated mouse models of autism and thus can potentially be used as a biomarker for diagnosing autism. In addition, these defects were shown to be synapse-specific, allowing for more focused future research. Lastly, BDNF defects can be tested for in the future and have been shown to be a potential drug target for curing autism.
Summary statement
I discovered that ERK-related protein defects were synapse-specific and that these defects can potentially be used both as a biomarker for diagnosing autism and as a drug target for curing autism.
Help received
I want to thank Dr. Christine Gall and graduate student Ronald Seese for their invaluable guidance and editing of my project. I also want to thank my parents and my science teachers, Mr. Knight and Ms. Bunch, for their continued support of my science education.
Awards (1)
Competition history
- CSEF 2012
Resources
Related projects
CSEF · 2012
Developing New Drugs to Treat Autism
CSEF · 2012
Exploring Neural-Immune Synergy: TNF Inhibition Protects Against Maternal Illness Induced Neuronal Dysfunction in Autism
ISEF · 2025
Above and Beyond the Autism of Today: Exploring a Retroelement Regulatory Hypothesis in Autism Spectrum Disorder
ISEF · 2014
Autism in Fruit Flies II: Behavior of Drosophila mGluR Pathway Mutants
ISEF · 2017
Autism and Genetics: Understanding the Role of AUTS2 in the Pathology of Autism Spectrum Disorder
CSEF · 2015
Electrophysiology-Based Screen to Discover Genes Involved in Synaptic Homeostasis
ISEF · 2026
Biophysical Computational Modeling of Neuronal Network Activity in Control and SHANK2-Linked Autism Brain Organoids
ISEF · 2020
Characterization of Learning and Memory Dysfunction in Mouse Models of Genetic and Acquired Epilepsy
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects